Experienced in Pyruvate Kinase Deficiency

Dr. Matthew Heeney

Hematology | Oncology
Dana-Farber Cancer Institute
450 Brookline Ave, 
Boston, MA 
Experienced in Pyruvate Kinase Deficiency
Dana-Farber Cancer Institute
450 Brookline Ave, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Matthew Heeney is a Hematologist and an Oncologist in Boston, Massachusetts. Dr. Heeney is rated as an Experienced provider by MediFind in the treatment of Pyruvate Kinase Deficiency. His top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemolytic Anemia, Hemoglobinopathy, and Splenectomy.

His clinical research consists of co-authoring 74 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Pyruvate Kinase Deficiency.

Specialties
Hematology
Oncology
Licenses
Pediatric Hematology-Oncology in MA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 7 Less Insurance Carriers -

Locations

Dana-farber Cancer Institute
450 Brookline Ave, Boston, MA 02215

Additional Areas of Focus

Dr. Heeney has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Prospective Phase II, Open-Label, Single-arm, Multicenter, Study to Assess Efficacy and Safety of SEG101 (Crizanlizumab), in Sickle Cell Disease Patients With Priapism (SPARTAN)
A Prospective Phase II, Open-Label, Single-arm, Multicenter, Study to Assess Efficacy and Safety of SEG101 (Crizanlizumab), in Sickle Cell Disease Patients With Priapism (SPARTAN)
Enrollment Status: Completed
Publish Date: January 13, 2026
Intervention Type: Drug
Study Drug: Crizanlizumab
Study Phase: Phase 2
A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea/Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive Crisis
A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea/Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive Crisis
Enrollment Status: Completed
Publish Date: October 16, 2025
Intervention Type: Drug
Study Drug: Crizanlizumab
Study Phase: Phase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study and Open-Label Extension of SC411 in Children With Sickle Cell Disease
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study and Open-Label Extension of SC411 in Children With Sickle Cell Disease
Enrollment Status: Unknown
Publish Date: January 31, 2019
Intervention Type: Drug
Study Drug: Docosahexanoic Acid (DHA)
Study Phase: Phase 2
A Phase II, Randomized, Placebo-Controlled Trial of Regadenoson in Sickle Cell Anemia
A Phase II, Randomized, Placebo-Controlled Trial of Regadenoson in Sickle Cell Anemia
Enrollment Status: Completed
Publish Date: February 07, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

74 Total Publications

A xeno-free red blood cell differentiation formula models sickle cell disease from somatically sourced patient iPSCs.
A xeno-free red blood cell differentiation formula models sickle cell disease from somatically sourced patient iPSCs.
Journal: Experimental hematology
Published: September 07, 2025
Similar Doctors
Distinguished in Pyruvate Kinase Deficiency
Dr. Peter Newburger
Hematology | Oncology
Distinguished in Pyruvate Kinase Deficiency
Dr. Peter Newburger
Hematology | Oncology

UMass Memorial Children's Medical Center

55 Lake Ave N, 
Worcester, MA 
 (33.6 miles away)
508-856-4225
Languages Spoken:
English
See accepted insurances

Peter Newburger is a Hematologist and an Oncologist in Worcester, Massachusetts. Dr. Newburger is rated as a Distinguished provider by MediFind in the treatment of Pyruvate Kinase Deficiency. His top areas of expertise are Infantile Neutropenia, Pyruvate Kinase Deficiency, Aase Syndrome, Splenectomy, and Bone Marrow Transplant.

Experienced in Pyruvate Kinase Deficiency
Dr. Richard Voit
Hematology | Oncology
Experienced in Pyruvate Kinase Deficiency
Dr. Richard Voit
Hematology | Oncology

Boston Children's Hospital

300 Longwood Ave, 
Boston, MA 
 (0.1 miles away)
617-355-6000
Languages Spoken:
English
See accepted insurances

Richard Voit is a Hematologist and an Oncologist in Boston, Massachusetts. Dr. Voit is rated as an Experienced provider by MediFind in the treatment of Pyruvate Kinase Deficiency. His top areas of expertise are Sickle Cell Disease, Anemia, Hereditary Neuroblastoma, and Neuroblastoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Heeney's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 30 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile